Yaupon submits NDA for mycosis fungoides topical gel
Yaupon Therapeutics has submitted a new drug application (NDA) to the US Food and Drug Administration for Yaupon's proprietary gel formulation—both greaseless and water-soluble—of mechlorethamine, and the FDA accepted the application.
Yaupon hopes to bring their gel to the US market as a treatment option against the early stages of a very common form of cutaneous T-cell non-Hodgkin's lymphoma known as mycosis fungoides.
Mechlorethamine is hardly a new drug for the treatment of mycosis fungoides (MF). It has been used as an intravenous chemotherapeutic agent against MF long enough to have become part of the standard treatment guidelines published by the National Comprehensive Cancer Network (nccn.org).
Yaupon's gel however would be the first topical formula of the drug. Previously, the FDA granted the gel orphan drug status.
Further reading
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
